Figure 2. CCR5-knockout mice are protected against TNBS-induced acute colitis.

(A,B) Severity of TNBS-induced colitis (weight loss and stool consistency) was reduced in CCR5^−/− mice. (C) Macroscopic inflammation. n = 6 per group (*P < 0.05, **P < 0.01, ***P < 0.005). (D) Absolute number of CD45⁺ and CD11b⁺ cells detected in the colonic LP of individual naïve and coltic mice. (E) Representative flow cytometry analysis of CCR5^+/+ mice treated with TNBS showing staining of total colonic leucocytes for CD11b+ cells (upper panel, after exclusion of MHC-II^high CD11c^high putative dendritic cells) and their relative expressions of MHC-II and GR1 (lower panel). (F) Absolute number of cells in the colonic LP corresponding to Population 1 (P1) (MHC-II⁺/Gr-1⁻/CD11b^int), Population 2 (P2) (MHC-II⁻/Gr-1⁻/CD11b^low) and Population 3 (P3) (MHC-II⁻/Gr-1⁺/CD11b^high) in untreated and TNBS coliticmice that were treated or not by oral administration of maraviroc. Data shown mean ± SE n = 3 per group (*P < 0.05, **P < 0.01, ***P < 0.005; two-tailed, unpaired Student’s t test).